In a report released on June 25, from UBS maintained a Buy rating on InSilico Medicine Cayman TopCo, with a price target of HK$77.00. The compa...
In a report released on June 25, from UBS maintained a Buy rating on InSilico Medicine Cayman TopCo, with a price target of HK$77.00. The company’s shares closed yesterday at HK$45.50.
Currently, the analyst consensus on InSilico Medicine Cayman TopCo is a Moderate Buy with an average price target of HK$76.90.
Read More on HK:3696:
Disclaimer & DisclosureReport an Issue
In a report released on May 15, from Bank of China maintained a Buy rating on Hua Hong Semiconductor Ltd., with a price target…
In a report released on June 11, from UBS maintained a Hold rating on Giant Biogene Holding Co. Ltd., with a price target of…
In a report released on June 25, from UBS maintained a Buy rating on CanSino Biologics, Inc. Class H, with a price target of…
In a report released on May 28, from Morgan Stanley maintained a Buy rating on Keymed Biosciences, Inc., with a price target of…
Citi analyst maintained a Buy rating on Giant Biogene Holding Co. Ltd. on June 17 and set a price target of HK$37.00. The…
In a report released on May 27, from UBS maintained a Buy rating on RoboSense Technology Company., Ltd, with a price target of…
